Recursion Pharmaceuticals (RXRX) Revenue (2020 - 2026)

Recursion Pharmaceuticals has reported Revenue for 7 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 56.11% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $66.4 million (up 11.07% YoY), and the FY2025 full-year result was $74.7 million, up 26.92% from the prior year.
• Revenue for Q1 2026 stood at $6.5 million, down from $35.5 million in the prior quarter.
• The five-year high for Revenue was $35.5 million in Q4 2025, with the low at $4.5 million in Q4 2024.
• Historically, Revenue has averaged $13.2 million across 5 years, with a median of $12.1 million in 2023.
• The largest YoY upside for Revenue was 681.74% in 2025 against a maximum downside of 80.16% in 2025.
• Recursion Pharmaceuticals' Revenue stood at $13.7 million in 2022, then retreated by 20.36% to $10.9 million in 2023, then plunged by 58.26% to $4.5 million in 2024, then surged by 681.74% to $35.5 million in 2025, then sank by 81.79% to $6.5 million in 2026.
• The last three Revenue figures came in at $6.5 million (Q1 2026), $35.5 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.